利特昔替尼(Ritlecitinib)治疗白癜风要吃多久？

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

Ritlecitinib is usually taken for about 24 weeks to treat vitiligo. However, since each vitiligo patient has a different condition and personal situation, the time for taking Ritlecitinib to treat vitiligo is not uniform.

About Ritlecitinib

It is an oral Janus kinase 3/tyrosine kinase expressed in the hepatocellular carcinoma family of inhibitors in parallel clinical development for alopecia areata, vitiligo, ulcerative colitis, Crohn's disease and rheumatoid arthritis.

Vitiligo is an acquired chronic skin depigmentation disease. It is mostly asymptomatic, characterized by amelanotic macules and plaques, and affects 0.5% to 2% of the world's population. The cause of vitiligo has not been clearly elucidated, and several theories have been proposed as to the cause of the disease.

With a deeper understanding of the pathogenesis of vitiligo, the latest information on its pathogenesis and treatment methods are reviewed, including topical and oral Janus kinase inhibitors, prostaglandins and their analogs, namely afamelantide, Wnt/β-catenin signaling agonists, and cell-based therapies. Ritlecitinib is registered for the treatment of vitiligo.

Ritlecitinib usage and dosage

The recommended dose of Ritlecitinib is 50 mg once a day, with or without food. Swallow the tablet whole; do not crush, break or chew Ritlecitinib.

If you miss a dose, you should replenish it immediately unless the interval between the next dose is less than 8 hours. In this case, you can skip the missed dose. Afterwards, re-administer the medication at regularly scheduled times.

Time to treat vitiligo with Ritlecitinib

The study showed that patients in the Ritlecitinib 50 mg group received 50 mg of Ritlecitinib daily during the 24-week extension period. The percentage change from baseline in the Facial Vitiligo Area Score Index in the Ritlecitinib 50 mg group was significantly different from the placebo.

Accelerated improvement was observed after treatment with 50 mg Ritlecitinib during the extension phase. No dose-dependent trends in treatment-emergent or serious adverse events were observed through 48 weeks of treatment. Therefore, Ritlecitinib needs to be taken for about 24 weeks or even longer to treat vitiligo.

Efficacy of Ritlecitinib in the treatment of vitiligo

Background: Vitiligo is an autoimmune depigmentation disease with no effective and safe treatment. Its pathogenesis has not been fully elucidated.

Purpose: This substudy of a randomized, double-blind, placebo-controlled Phase 2b trial (NCT03715829) evaluated the effects of the oral JAK3/TEC family kinase inhibitor Ritlecitinib on skin and blood biomarkers in patients with non-segmental vitiligo (NSV).

Methods: Sixty-five adults with NSV participated in this substudy and received 24 weeks of daily treatment with placebo (n=14) or Ritlecitinib, with or without a 4-week loading dose: 200 (loading dose)/50 mg (n = 13), 100/50 mg (n = 12), 50 mg (n = 11), 30 mg (n=8) or 10mg (n=6). Skin (lesional and non-lesional) biopsy samples were obtained at baseline, 4 weeks, and 24 weeks. Changes in skin and blood molecular and cellular biomarkers from baseline to weeks 4 and 24 were assessed by RNA sequencing, quantitative real-time PCR, proteomic analysis, and flow cytometry.

Results: Ritlecitinib treatment groups showed downregulation of immune biomarkers and upregulation of melanocyte-related markers at weeks 4 and 24 compared with baseline and/or placebo. CD3+/CD8+ T cell infiltration was significantly reduced, and the expression of melanocyte markers (tyrosinase; Melan-A) in NSV lesions in the 50 mg Ritlecitinib group.

In diseased skin, T cell activation, NK, cytotoxicity and regulatory markers P < .05. TH1 and TH2 markers were also dose-dependently downregulated in lesional skin and blood (P < .05). Changes in immune biomarkers associated with clinical response.

Conclusion: Ritlecitinib down-regulated pro-inflammatory biomarkers and increased melanocyte production in the skin and blood of NSV patients, suggesting its therapeutic potential. Ritlecitinib-mediated changes were positively correlated with clinical response.

Notes

1. Lifestyle: Patients with vitiligo should avoid staying up late and avoid skin damage such as trauma, exposure to the sun, and local friction. Avoid contact with phenolic compounds. You can eat vegetables and fruits rich in vitamin C appropriately to maintain a balanced diet and nutrition. Supplementing with vitamin B, vitamin E, folic acid, calcium, etc. may be helpful.

2. Treatment: Patients should strictly follow the doctor's instructions and take medication on time and in accordance with the dosage. They are not allowed to increase or decrease the dosage of drugs without permission. If you are using other medications during medication, you should consult your doctor in advance to avoid drug interactions.

3. Regular review: Patients should follow the doctor's instructions for regular follow-up. If symptoms recur, they need to seek medical treatment in time.

Summary

Therefore, the specific duration of Ritlecitinib (Ritlecitinib) treatment for vitiligo should be clarified under the guidance of a doctor based on the patient's condition, and patients should not stop taking the medication without authorization.